Avoiding relapse of AML has been more challenging than intuitively anticipated, and early trials using strategies that aimed at reducing relapse risk did not significantly alter routine practice.8 However, renewed interest in relapse prevention is demonstrated by recent large trials that have evaluated the fms-related tyrosine kinase 3 (FLT3) inhibitors midostaurin9 and quizartinib10 as well as an oral formulation of azacitidine11 in the postconsolidation phase. Here, FLT3 is linked to acute myeloid leukemia.